How does ResMed (RMD) make money?

ResMed (RMD) generates revenue primarily from Sleep And Respiratory, which accounted for 87.9% of total revenue in TTM through Q1 2026. The company reported $5.54B in revenue and converted 27.4% of it into net profit, equivalent to roughly $1.52B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of ResMed (RMD)?

ResMed (RMD) reported a gross profit margin of 61.7% in TTM through Q1 2026, equivalent to $3.42B in gross profit on $5.54B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of ResMed (RMD)?

ResMed (RMD) reported an operating profit margin of 34.3% in TTM through Q1 2026, equivalent to $1.90B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of ResMed (RMD)?

ResMed (RMD) reported a net profit margin of 27.4% in TTM through Q1 2026, equivalent to $1.52B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is ResMed (RMD) profitable?

Yes. ResMed (RMD) reported $1.52B in net income for TTM through Q1 2026, with a net profit margin of 27.4%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does ResMed (RMD) invest in research and development?

ResMed (RMD) invested $359.00M in research and development during TTM through Q1 2026, roughly 6.5% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does ResMed (RMD) spend on capital expenditures?

ResMed (RMD) spent $135.74M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 2.5% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does ResMed (RMD) generate?

ResMed (RMD) generated $1.75B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 31.7%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of ResMed (RMD)?

ResMed (RMD) had an effective tax rate of 20.2% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of ResMed (RMD)?

ResMed (RMD) reports revenue across 2 reportable product segments, led by Sleep And Respiratory at 87.9% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How ResMed Makes Money: 2026 Visual Revenue Map

ResMed (RMD) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 30, 2026).

ResMed discloses geographic revenue only in annual filings. to view the full breakdown.

ResMed (RMD) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for ResMed (RMD) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Sleep And Respiratory	$4.87B	87.9%
Residential Care Software	$668.55M	12.1%
Total	$5.54B	100%

Sleep And Respiratory$4.87B
Residential Care Software$668.55M
Total$5.54B

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, ResMed (RMD) reports revenue across 2 operating segments; the largest segment was Sleep And Respiratory at 87.9%, followed by Residential Care Software (12.1%).

Frequently asked questions

Data & methodology

ResMed (RMD) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation